FDA Cites Celgene For Tardy Adverse Event Reporting On Thalomid
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene has hired a new contractor to process adverse event reports for thalidomide, although the agency says it will have to “assess the adequacy of the correction during a future inspection.” An FDA letter cites 82 instances of delayed reports.
You may also be interested in...
Celgene Thalomid Multiple Myeloma sNDA Is "Approvable"
Celgene said that it will submit a completed study which compares thalidomide plus dexamethasone to dexamethasone alone in previously untreated patients, as well as additional data. Accelerated approval is possible in six to nine months, the company says.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.